They offer real, life-changing benefits for manyyet come with side effects, high costs, and long-term uncertainties
Meanwhile, Umar Razzaq, UK-based pharmacist and co-founder of pharmacyonline.co.uk, noticed a pattern where its the GLP-1 users who are already comfortable with needles that are now branching out into other peptides theyve seen on social media
This creates a gap in which higher valuations are not yet offsetting volume reductions
Highlighting reduced polypharmacy and improved outcomes strengthens value propositions with providers and payers
Keep in mind that about 14% of people taking semaglutide may lose less than 5% of their body weight after 68 weeks, so for some, exploring alternatives like tirzepatide designed to target multiple hormone receptors might be necessary
Morroniside, an iridoid glycoside derived from the medicinal herb Cornus officinalis , is a potent orthosteric agonist of GLP-1R with significant anti-hypersensitivity effects